UBS Group’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $358K | Sell |
96,519
-139,926
| -59% | -$519K | ﹤0.01% | 5093 |
|
|
2025
Q1 | $764K | Buy |
236,445
+138,881
| +142% | +$449K | ﹤0.01% | 4390 |
|
|
2024
Q4 | $543K | Buy |
97,564
+17,275
| +22% | +$96.2K | ﹤0.01% | 4632 |
|
|
2024
Q3 | $868K | Buy |
80,289
+13,149
| +20% | +$142K | ﹤0.01% | 3700 |
|
|
2024
Q2 | $1.41M | Sell |
67,140
-307,050
| -82% | -$6.44M | ﹤0.01% | 3124 |
|
|
2024
Q1 | $11.9M | Buy |
374,190
+288,139
| +335% | +$9.18M | ﹤0.01% | 1502 |
|
|
2023
Q4 | $1.74M | Buy |
86,051
+41,154
| +92% | +$834K | ﹤0.01% | 2980 |
|
|
2023
Q3 | $572K | Sell |
44,897
-8,953
| -17% | -$114K | ﹤0.01% | 3518 |
|
|
2023
Q2 | $973K | Buy |
53,850
+1,451
| +3% | +$26.2K | ﹤0.01% | 3338 |
|
|
2023
Q1 | $901K | Buy |
52,399
+11,671
| +29% | +$201K | ﹤0.01% | 3271 |
|
|
2022
Q4 | $905K | Buy |
+40,728
| New | +$905K | ﹤0.01% | 3221 |
|
|
2022
Q3 | – | Sell |
-35
| Closed | – | – | 9342 |
|
|
2022
Q2 | $0 | Sell |
35
-70,199
| -100% | – | ﹤0.01% | 9377 |
|
|
2022
Q1 | $1.06M | Buy |
70,234
+884
| +1% | +$13.4K | ﹤0.01% | 3174 |
|
|
2021
Q4 | $1.52M | Buy |
69,350
+68,094
| +5,421% | +$1.49M | ﹤0.01% | 3105 |
|
|
2021
Q3 | $34K | Buy |
+1,256
| New | +$34K | ﹤0.01% | 5522 |
|
|
2021
Q2 | – | Sell |
-20,592
| Closed | -$893K | – | 8344 |
|
|
2021
Q1 | $893K | Buy |
+20,592
| New | +$893K | ﹤0.01% | 3471 |
|